News

Ihr Ansprechpartner

Manager PR & Communications Jan Phillip Denkers

Indivumed is using nRavel™ for target discovery and drug development programs. (Picture: ©Jackie Niam/stock.adobe.com)

Indivumed Launches the nRavel AI Platform

Indivumed GmbH (“Indivumed”) today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines ...

Weiterlesen …
New Entity to Develop Therapeutics Targeting RAS Pathway Mutations in Colorectal Cancer (Picture: © Indivumed GmbH)

Indivumed Joins KHR Biotech

Indivumed GmbH (“Indivumed”) CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR ...

Weiterlesen …